Neuro-oncology advances

Level I and II deficits-A clinical survey on international practice of awake craniotomy and definitions of postoperative "major" and "minor" deficits.

Neuro-oncology advances

Vooijs M, Robertson FC, Blitz SE, Jungk C, Krieg SM, Schucht P, De Vleeschouwer S, Vincent AJPE, Berger MS, Nahed BV, Broekman MLD, Gerritsen JKW

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.

Neuro-oncology advances

Gittleman H, Cioffi G, Chunduru P, Molinaro AM, Berger MS, Sloan AE, Barnholtz-Sloan JS

Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop.

Neuro-oncology advances

Penas-Prado M, Wu J, Cahill DP, Brat DJ, Costello JF, Kluetz PG, Cairncross JG, van den Bent M, Verhaak RGW, Aboud O, Burger P, Chang SM, Cordova C, Huang RY, Rowe LS, Taphoorn MJB, Gilbert MR, Armstrong TS, NCI-CONNECT Oligodendroglioma Workshop

Pages